Patents by Inventor Hazel Hunt

Hazel Hunt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glucocorticoid receptor modulators to treat pancreatic cancer
    Patent number: 10646474
    Abstract: Methods and compositions for treating a subject hosting a non-ACTH-secreting pancreatic tumor are disclosed. The methods include administering to the subject a chemotherapeutic agent and a glucocorticoid receptor modulator (GRM), preferably a selective glucocorticoid receptor modulator (SGRM), to reduce the tumor load in the subject. The GRM may be a nonsteroidal GRM, and may be a nonsteroidal SGRM. The non-ACTH-secreting pancreatic tumor may be an exocrine pancreatic tumor. The nonsteroidal SGRM may be a nonsteroidal compound comprising: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure. Pharmaceutical compositions comprising a chemotherapeutic agent and a GRM are disclosed. The GRM in such pharmaceutical compositions may be a nonsteroidal GRM, and may be a SGRM, such as a nonsteroidal SGRM.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: May 12, 2020
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Hazel Hunt, Thaddeus S. Block
  • Methods for diagnosing and assessing treatment for Cushing's syndrome
    Patent number: 10604807
    Abstract: Methods are provided for assessing a clinical response to a glucocorticoid receptor antagonist (GRA) in a human subject and for diagnosing Cushing's syndrome.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: March 31, 2020
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Joseph K. Belanoff, Hazel Hunt, John Francis Unitt, Andreas G. Moraitis
  • Glucocorticoid receptor modulators to treat cervical cancer
    Patent number: 10568880
    Abstract: Methods for treating a subject having a cancerous tumor are disclosed. The methods comprise administering to the subject an effective amount of a non-steroidal selective glucocorticoid receptor modulator (SGRM) and an effective amount of a chemotherapeutic agent. The tumor may be cervical cancer. The SGRM may be a fused azadecalin. In embodiments, the SGRM may be a heteroaryl ketone fused azadecalin or an octahydro fused azadecalin.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: February 25, 2020
    Assignee: Corcept Therapeutics, Inc.
    Inventor: Hazel Hunt
  • HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS
    Publication number: 20200009131
    Abstract: The present invention provides heteroaryl ketone fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
    Type: Application
    Filed: September 13, 2019
    Publication date: January 9, 2020
    Inventors: Hazel Hunt, Tony Johnson, Nicholas Ray, Iain Walters
  • GLUCOCORTICOID RECEPTOR MODULATORS TO TREAT PANCREATIC CANCER
    Publication number: 20200000771
    Abstract: Methods and compositions for treating a subject hosting a non-ACTH-secreting pancreatic tumor are disclosed. The methods include administering to the subject a chemotherapeutic agent and a glucocorticoid receptor modulator (GRM), preferably a selective glucocorticoid receptor modulator (SGRM), to reduce the tumor load in the subject. The GRM may be a nonsteroidal GRM, and may be a nonsteroidal SGRM. The non-ACTH-secreting pancreatic tumor may be an exocrine pancreatic tumor. The nonsteroidal SGRM may be a nonsteroidal compound comprising: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure. Pharmaceutical compositions comprising a chemotherapeutic agent and a GRM are disclosed. The GRM in such pharmaceutical compositions may be a nonsteroidal GRM, and may be a SGRM, such as a nonsteroidal SGRM.
    Type: Application
    Filed: August 23, 2019
    Publication date: January 2, 2020
    Inventors: Hazel Hunt, Thaddeus S. Block
  • Methods of preparing regioselective N-alkyl triazoles
    Patent number: 10494349
    Abstract: Methods of preparing N-2 alkylated triazoles substantially free from N-1 and N-3 alkylated triazoles are disclosed. The methods include one-step alkylation methods and two-step alkylation methods for the preparation of N-alkylated triazoles.
    Type: Grant
    Filed: April 22, 2019
    Date of Patent: December 3, 2019
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Hazel Hunt, Arjen Christiaan Breman, Bas Wilhelmus Theodorus Gruijters
  • Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
    Patent number: 10456392
    Abstract: The present invention provides heteroaryl ketone fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: October 29, 2019
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Hazel Hunt, Tony Johnson, Nicholas Ray, Iain Walters
  • METHODS OF PREPARING REGIOSELECTIVE N-ALKYL TRIAZOLES
    Publication number: 20190322629
    Abstract: Methods of preparing N-2 alkylated triazoles substantially free from N-1 and N-3 alkylated triazoles are disclosed. The methods include one-step alkylation methods and two-step alkylation methods for the preparation of N-alkylated triazoles.
    Type: Application
    Filed: April 22, 2019
    Publication date: October 24, 2019
    Inventors: Hazel Hunt, Arjen Christiaan Breman, Bas Wilhelmus Theodorus Gruijters
  • Glucocorticoid receptor modulators to treat pancreatic cancer
    Patent number: 10449178
    Abstract: Methods and compositions for treating a subject hosting a non-ACTH-secreting pancreatic tumor are disclosed. The methods include administering to the subject a chemotherapeutic agent and a glucocorticoid receptor modulator (GRM), preferably a selective glucocorticoid receptor modulator (SGRM), to reduce the tumor load in the subject. The GRM may be a nonsteroidal GRM, and may be a nonsteroidal SGRM. The non-ACTH-secreting pancreatic tumor may be an exocrine pancreatic tumor. The nonsteroidal SGRM may be a nonsteroidal compound comprising: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure. Pharmaceutical compositions comprising a chemotherapeutic agent and a GRM are disclosed. The GRM in such pharmaceutical compositions may be a nonsteroidal GRM, and may be a SGRM, such as a nonsteroidal SGRM.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: October 22, 2019
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Hazel Hunt, Thaddeus S. Block
  • Glucocorticoid receptor modulators to treat cervical cancer
    Patent number: 10413540
    Abstract: Methods for treating a subject having a cancerous tumor are disclosed. The methods comprise administering to the subject an effective amount of a non-steroidal selective glucocorticoid receptor modulator (SGRM) and an effective amount of a chemotherapeutic agent. The tumor may be cervical cancer. The SGRM may be a fused azadecalin. In embodiments, the SGRM may be a heteroaryl ketone fused azadecalin or an octahydro fused azadecalin.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: September 17, 2019
    Assignee: Corcept Therapeutics, Inc.
    Inventor: Hazel Hunt
  • OCTAHYDRO FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS
    Publication number: 20190241563
    Abstract: The present invention provides octahydro fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
    Type: Application
    Filed: April 12, 2019
    Publication date: August 8, 2019
    Inventors: Hazel Hunt, Iain Walters, Benoit Gourdet
  • Octahydro fused azadecalin glucocorticoid receptor modulators
    Patent number: 10323034
    Abstract: The present invention provides octahydro fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: June 18, 2019
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Hazel Hunt, Iain Walters, Benoit Gourdet
  • GLUCOCORTICOID RECEPTOR MODULATORS TO TREAT PANCREATIC CANCER
    Publication number: 20190151288
    Abstract: Methods and compositions for treating a subject hosting a non-ACTH-secreting pancreatic tumor are disclosed. The methods include administering to the subject a chemotherapeutic agent and a glucocorticoid receptor modulator (GRM), preferably a selective glucocorticoid receptor modulator (SGRM), to reduce the tumor load in the subject. The GRM may be a nonsteroidal GRM, and may be a nonsteroidal SGRM. The non-ACTH-secreting pancreatic tumor may be an exocrine pancreatic tumor. The nonsteroidal SGRM may be a nonsteroidal compound comprising: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure. Pharmaceutical compositions comprising a chemotherapeutic agent and a GRM are disclosed. The GRM in such pharmaceutical compositions may be a nonsteroidal GRM, and may be a SGRM, such as a nonsteroidal SGRM.
    Type: Application
    Filed: January 29, 2019
    Publication date: May 23, 2019
    Inventors: Hazel Hunt, Thaddeus S. Block
  • FATTY LIVER DISEASE TREATMENT USING GLUCOCORTICOID AND MINERALOCORTICOID RECEPTOR ANTAGONISTS
    Publication number: 20190151318
    Abstract: The present invention provides treatment of fatty liver disease using a class of pyrimidinedione cyclohexyl compounds.
    Type: Application
    Filed: January 24, 2019
    Publication date: May 23, 2019
    Inventors: Joseph K. Belanoff, Hazel Hunt, Onno C. Meijer, José Van den Heuvel
  • OCTAHYDRO FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS
    Publication number: 20190135805
    Abstract: The present invention provides octahydro fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
    Type: Application
    Filed: July 16, 2018
    Publication date: May 9, 2019
    Inventors: Hazel Hunt, Iain Walters, Benoit Gourdet
  • Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
    Patent number: 10238659
    Abstract: The present invention provides treatment of fatty liver disease using a class of pyrimidinedione cyclohexyl compounds.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: March 26, 2019
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Joseph K. Belanoff, Hazel Hunt, Onno C. Meijer, José van den Heuvel
  • THE USE OF GLUCOCORTICOID RECEPTOR MODULATORS TO POTENTIATE CHECKPOINT INHIBITORS
    Publication number: 20190083486
    Abstract: This invention provides a method that combines a checkpoint inhibitor and a glucocorticoid receptor modulator to treat cancer, e.g., a checkpoint inhibitor sensitive cancer.
    Type: Application
    Filed: February 28, 2017
    Publication date: March 21, 2019
    Inventor: Hazel Hunt
  • GLUCOCORTICOID RECEPTOR MODULATORS TO TREAT CERVICAL CANCER
    Publication number: 20190076424
    Abstract: Methods for treating a subject having a cancerous tumor are disclosed. The methods comprise administering to the subject an effective amount of a non-steroidal selective glucocorticoid receptor modulator (SGRM) and an effective amount of a chemotherapeutic agent. The tumor may be cervical cancer. The SGRM may be a fused azadecalin. In embodiments, the SGRM may be a heteroaryl ketone fused azadecalin or an octahydro fused azadecalin.
    Type: Application
    Filed: November 9, 2018
    Publication date: March 14, 2019
    Inventor: Hazel Hunt
  • HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS
    Publication number: 20190060305
    Abstract: The present invention provides heteroaryl ketone fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
    Type: Application
    Filed: February 6, 2018
    Publication date: February 28, 2019
    Inventors: Hazel Hunt, Tony Johnson, Nicholas Ray, Iain Walters
  • Glucocorticoid receptor modulators to treat pancreatic cancer
    Patent number: 10213414
    Abstract: Methods and compositions for treating a subject hosting a non-ACTH-secreting pancreatic tumor are disclosed. The methods include administering to the subject a chemotherapeutic agent and a glucocorticoid receptor modulator (GRM), preferably a selective glucocorticoid receptor modulator (SGRM), to reduce the tumor load in the subject. The GRM may be a nonsteroidal GRM, and may be a nonsteroidal SGRM. The non-ACTH-secreting pancreatic tumor may be an exocrine pancreatic tumor. The nonsteroidal SGRM may be a nonsteroidal compound comprising: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure. Pharmaceutical compositions comprising a chemotherapeutic agent and a GRM are disclosed. The GRM in such pharmaceutical compositions may be a nonsteroidal GRM, and may be a SGRM, such as a nonsteroidal SGRM.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: February 26, 2019
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Hazel Hunt, Thaddeus S. Block